Krystal Biotech (KRYS) Total Liabilities (2016 - 2026)

Krystal Biotech has reported Total Liabilities for 11 years, with the latest figure at $141.5 million in Q2 2026.

• Total Liabilities for Q2 2026 came in at $141.5 million, up 44.78% year-over-year; the trailing twelve-month figure through Jun 2026 was $141.5 million (up 44.78% YoY), and the FY2025 annual result was $114.2 million, up 4.36% from the prior year.
• Total Liabilities improved to $141.5 million in Q2 2026, from $120.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $141.5 million in Q2 2026 and troughed at $30.9 million in Q2 2023.
• A 5-year average of $74.1 million and a median of $73.5 million in 2022 frame the typical range for Total Liabilities.
• The widest annual swing landed in 2022, when Total Liabilities jumped 452.48%; it then sank 38.11% in 2023.
• A 5-year view of Total Liabilities shows it stood at $36.2 million in 2022, then climbed by 9.65% to $39.7 million in 2023, then soared by 175.62% to $109.5 million in 2024, then advanced by 4.36% to $114.2 million in 2025, then gained by 23.89% to $141.5 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $141.5 million in Q2 2026, $120.2 million in Q1 2026, and $114.2 million in Q4 2025.